Pd


 

We picked Adamas Pharmaceuticals (ADMS) stock in our portfolio last year (see initiation article with full details).

We are reiterating Buy on Adamas stock ahead of PDUFA.

ADS amantadine CEO drug levodopa lid PD release stock treatment

 

Importantly, the reaction to MYSTIC might be overly strong, and we'll take a look at why.

Last week, AZN announced top-line data from their phase 3 MYSTIC study, which was a randomized study with three treatment arms: durvalumab alone, durvalumab plus tremelimumab, and chemotherapy.

AZN durvalumab inhibitor line MYSTIC Pacific patients PD PD L1 tumor

 

Acorda Therapeutics (ACOR) is a $1 billion market cap company focused on developing inhalation therapies to improve the lives of those afflicted with neurological disorders.

Acorda's lead candidate, CVT-301 (INBRIJA), met its primary endpoint showing statistically significant improvement of motor function compared to placebo in its phase 3 SPAN-PD clinical trial for Parkinson's disease (PD).

ACOR candidate CVT development drug Inbrija market PD Phase treatment

 

The immune checkpoint inhibitors have created a fast-running revolution in the world of cancer research. Merck (NYSE:MRK) has channeled this agent into a wide variety of treatment settings, most recently bladder cancer.

agent BMY cancer high L1 MRK MSI patient PD tumor

 

What to Expect From Merck at ASCO [0.09]

Posted on May 23, 2017, 2:10 p.m. by 24/7 Wall St. @ [source]

The premier event for biotech and pharma companies in 2017 is just around the corner.

Here, 24/7 Wall St. is specifically taking a look at Merck & Co. Inc. (NYSE: MRK) and what Credit Suisse sees happening for this pharma giant at ASCO.

abstract ASCO cancer combination Incyte June Keytruda Merck PD perspective

 

Why Syndax Shares Are Rallying [0.06]

Posted on May 17, 2017, 2:35 p.m. by 24/7 Wall St. @ [source]

Shares of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) saw a huge gain on Wednesday after the firm gave an update on its non-small cell lung cancer (NSCLC) midstage trial. Specifically, the company announced that Encore 601 has met the prespecified objective response threshold to advance into the second stage of the Phase 2 trial and will reopen enrollment immediately.

enrollment L1 NSCLC objective patients PD previously response therapy trial

 

Italy Falls Out of Love With Euro: Beppe Grillo on the Rise [0.07]

Posted on March 22, 2017, 2:35 p.m. by MishTalk @ [source]

Recent polls for Italian politicians supporting the eurozone and EU have collapsed.

Pro-Europe polls are highly likely to get worse as a further splintering of Matteo Renzi’s PD party takes place.

election eurozone Italian Italy left majority party PD poll Star Movement

 

Recent polls for Italian politicians supporting the eurozone and EU have collapsed.

Pro-Europe polls are highly likely to get worse as a further splintering of Matteo Renzi’s PD party takes place.

election eurozone Italian Italy left majority party PD poll Star Movement

 

The Financial Times reports on the Rebellion that Threatens to Split Italy’s Democratic Party.

The immediate impact would be a loss of 6 percentage points, or more, support for PD, putting Beppe Grillo’s Five Star Movement solidly in the lead.

Bersani Corriere dissidents Italian left Mr party PD Rebel Renzi

 

Italy Increasingly Likely to Abandon the Euro [0.03]

Posted on Feb. 3, 2017, 10:26 p.m. by MishTalk @ [source]

An analysis of the political setup in Italy shows eurosceptics are on the verge of taking control of the country.

Former prime minister Matteo Renzi stepped down in December after holding a referendum that failed miserably.

early election electoral Grillo Italian movement parliament party PD Renzi star

 

Implications of BMS's problems for biotechs and the market at large are also discussed.

Now there is concern that Opdivo plus another immunotherapy it markets, Yervoy, may not be working especially well together in treating cancer.

benefit BMY compete early Keytruda L1 MRK oncology Opdivo PD